Brief Communication

Expression profiles of sporulation genes in multidrug-resistant *Bacillus* **species isolated from intensive care units of Ghanaian hospital**

Abiola Isawumi1,2 , Eunice Ampadubea Ayerakwa1,2, Molly Kukua Abban1,2 and Lydia Mosi^{1,2}^D

¹West African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Volta Road, P.O. Box LG 54, Legon, Accra, Ghana;
²Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Box LG 54, Legon, Accra, Ghana

Corresponding author: Abiola Isawumi. Email: isawumiabiola@gmail.com

Impact statement

Sporulation genes have been limited to inducing sporulation or spore formation during extreme environmental conditions; however, these genes could also be implicated in antimicrobial resistance (AMR). They could serve as potential "resistance" markers and obstruct antibiotic action. Although, the phenotypic property of spores may not be evident during antibiotic treatment; however, the expression of the markers could facilitate strain survival in the presence of antibiotics. Generally, little emphasis has been placed on the role of sporulation markers mediating AMR, this study provided insights that can possibly bridge this gap.

Abstract

Sporulating bacteria such as *Bacillus* spp. have contributed to severity of opportunistic hospital acquired infections, including postoperative wounds and respiratory tract infections. This study determines the expression profiles of sporulation markers in multidrug-resistant *Bacillus* spp. isolated from Ghanaian hospital environments. Antimicrobial resistance (AMR) profiles of the bacteria were determined with disk diffusion and broth microdilution. Primer-specific polymerase chain reaction (PCR) amplification was used to profile the sporulation markers, and quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used for the expression of the sporulation markers at different antibiotic concentrations. The strains are multidrug resistant (70–100%) to at least two of the eight classes of the antibiotics tested including cephalosporins, penicillin, aminoglycosides, and glycopeptide. The strains showed different resistance patterns to all the tested antibiotics, which might indicate diverse resistance mechanisms. Common (*spoVK spoVE*, *spoJ*, and *sigF*) and not commonly (*sigJ*, *soJ*, *yrbC*, and *yjcE*) reported

sporulation markers were detected in the strains. The study showed an association of the sporulation markers with AMR as indicated by their expression profiles.

Keywords: Sporulation, antimicrobial resistance, sporulation genes, *Bacillus* spp., hospital environment, spores, multidrug

Experimental Biology and Medicine **2023; 248: 501–507. DOI: 10.1177/15353702231160336**

Introduction

Bacteria have developed diverse survival mechanisms including spore formation, and this aids the bacteria to display resistance to antimicrobial agents, chemicals, and ultraviolet (UV) radiation.1 *Bacillus* species particularly *B. subtilis*, *B. cereus*, and *B. thuringiensis* are known for rapid spore formation.2 *Bacillus subtilis* as a model spore-forming bacterium differentiates into a dormant stress-resistant spore in harsh environmental conditions, such as high temperature and pressure, nutrient deprivation, and carbon or nitrogen starvation.3,4 Spore of various *Bacillus* species are resistant to conventional antibiotics, could cause food poisoning and human diseases, making sporulating bacteria a serious public health concern.4,5

In hospital environments where diverse bacteria are emerging and resistance to antibiotics is on the rise, 6 sporulation has been associated with hospital acquired infections including postoperative wound, sepsis, bacteremia, respiratory tract, and other opportunistic infections.7 While sporulation helps bacterial reproduction, in enclosed hospital intensive care unit (ICU), sporulating bacteria takes advantage of environmental dispersal agents such as fomites for spore propagation and distribution.8 Invasive devices and other medical handy-tools can harbor spores and spread infectious agents to immunocompromised and critically ill inpatients in the ICU.8

Bacillus subtilis can survive for months on hospital flat surfaces, and its sporulation machinery has been traced to its genetic components.9 Sporulation genes such as *SpoIIIE*, *SpoVE*, *SpoVR*, and *SpoVK* are turned-on when *B. subtilis* is exposed to environmental stresses including overuse of antibiotics, a common practice in the ICU.10 These genes and a few others are involved in different spore formation stages upon expression which regulates sporulation and contributes to bacterial virulence and antimicrobial resistance (AMR).¹⁰⁻¹² In Ghanaian hospital environments where diverse bacterial pathogens are emerging including *Bacillus* species, this study aims to characterize sporulation markers and determine AMR expression profiles of *Bacillus* species isolated from hospital environments in Ghana.

Materials and methods

Bacterial strains information

Archived environmental *B. subtilis* and *B. cereus* were used in this study. The strains were obtained from AbiMosi™ Bacterial Culture Library at West African Centre for Cell Biology of Infectious Pathogens at the University of Ghana, where the study was also conducted. The strains, isolated from Ghanaian hospital fomites, were identified using MALDI-TOF and 16S rRNA amplification previously described by Schröttner et al.¹³ All the strains were revived in Luria Bertani media (37°C for 24h, 5% CO₂) (Oxoid, England, CM0003) at the onset of the experiments.

AMR profiling

Antibiotic susceptibility test was performed using the standard Kirby–Bauer disk diffusion previously described Abiola et al.14 Briefly, the test strains were grown overnight in sterile Mueller–Hinton broth (Sigma M7408-500G; PCode: 1001876334) and optical density was standardized to 0.5 at 600 nm. Sterile Mueller–Hinton agar plates (Oxoid, Basingstoke, UK) were seeded with the standardized culture and antibiotic disks (vancomycin [30µg], trimethoprim [25 µg], penicillin [15 µg], amoxicillin [10 µg], ampicillin [10 µg], erythromycin [15 µg], chloramphenicol [30µg], gentamicin [10µg], cloxacillin [10µg], tetracycline [30µg], ceftriaxone [10µg]) (Mast Diagnostics, Mast Group Ltd., Merseyside, UK) were aseptically placed on the culture plates (incubation, 37°C for 24h). The zone of inhibition was measured with a meter rule (CLSI, 12th Edition) and data presented represents two independent experiments with three replicates. *B. subtilis ATCC 23857* was used as a standard control. Percentage resistance was expressed as the ratio of antibiotics resisted (resistance to available antibiotics) by the test strains to the total number of antibiotics tested or available as treatment option multiplied by 100. Also, fractional resistance to the tested antibiotics was determined with a broth microdilution and spotting assay. Briefly, $100 \mu L$ of the overnight Mueller–Hinton cultured strains standardized to 0.5 OD (600 nm) was added to 100μ L of antibiotics in a 96-well plate at test concentrations previously stated and incubated overnight at 37°C. OD was determined relative to the strain in the control wells (without the antibiotics) to determine bacterial survival in the presence of the antibiotics. $5-10 \mu L$ of $0.1 v/v$ of the culture in the resistant wells was spotted on Mueller–Hinton agar; colonies were counted relative to the controls. The fractional resistance for each of

the antibiotics was expressed as the percentage of colonies from the antibiotic resistant wells relative to the control without the antibiotics.

Sporulation genes profiling

Sporulation markers *yrbC*, *sigF*, *sigA*, *spsE*, *spovT*, *spoVK*, *spo0J*, *spoIIIE*, *cotA*, *spsK*, *cotSA*, *spoVE*, *soJ*, *spoIIIAB*, *spo0M*, *spsJ*, *cgeE*, and *spo0A* were profiled with polymerase chain reaction (PCR). Bacterial DNA extraction kits (Zymo Research, Irvine, CA, USA) and sporulation genes specific primers (S1) were synthesized by Inqaba Biotech (South Africa). The PCR amplification reaction mixture was a total volume of 25μL, containing 5μL of PCR buffer, 0.5μL of deoxynucleoside triphosphates (dNTPs), 0.5μ L of forward and reverse primer each, 15.87μL of distilled water, 0.13μL of Taq polymerase, and 2.5μL of template DNA. Negative control was the reaction buffer without the DNA template and positive control was the PCR amplicon from *B. subtilis ATCC 23857*. The PCR conditions included initial enzyme activation at 95°C for 10 min, followed by 40 cycles of amplicon denaturation at 95°C for 15 s, primer annealing at 60–65°C for 30 s to 1min and elongation at 60°C for 1min with final extension at 60°C for 1min.15 Amplification was performed in a thermocycler (Biometra, Gottingen, Germany). PCR products were separated on 1% agarose gel stained with 5μL of Gel Red (Biotium – Glowing Products for Science, Fremont, CA, USA). The amplified PCR products were visualized under the UV transilluminator Imager (Amershan™ Imager 600, Tokyo, Japan).

Determination of minimum inhibitory concentrations and antibiotic stress assay

To determine the levels of AMR and if the sporulation markers contribute to resistance, minimum inhibitory concentrations of the strains at different antibiotic concentrations were determined with broth microdilution. Briefly, the strains were cultured in Mueller–Hinton broth overnight at 37°C and standardized to OD of 0.5 (600nm). Following the CLSI standard as previously indicated, 100µL of the culture was added to 100 µL of double concentrations of antibiotics at 10–160µg/mL (cloxacillin, ceftriaxone, amoxicillin and ampicillin), 15-120 µg/mL (penicillin and erythromycin), 25–200µg/mL (trimethoprim), 30–240µg/mL (tetracycline, gentamicin, chloramphenicol, and vancomycin) in a 96-well plate (incubation at 37°C, 24h, 120r/min). Minimum inhibitory concentration was determined using the percentage of the OD (600nm) of test strain to OD of control. The percentage $OD < 10$ was the assigned minimum inhibitory concentration (MIC) of the strains at the specific concentration. To determine if the sporulation genes are expressed and induced sporulation under antibiotic stress, the strains were exposed to high concentrations of antibiotics to which they displayed 100% levels of resistance and higher minimum inhibitory concentrations. The strains were exposed to $2\times$ and $4\times$ MIC in broth microdilution as previously stated. Subsequently, the stressed variants were harvested by spreading 10 µL of the culture on LB agar plate and incubated overnight at 37°C. Highly resistant colonies of the survived isolates were selected for RNA extraction.

Total RNA was extracted from the multidrug-resistant *B. cereus* and *B. subtilis* with Trizol. Briefly, the cells were harvested in 1mL of Trizol (TRIzol™, Invitrogen, Waltham, MA, USA) and incubated at room temperature for 5min. 200µL of chloroform was added and vigorously shaken for 15s. Subsequently, the samples were incubated at room temperature for 2–5min and centrifuged at 12,000*g* for 15min at 4°C. The upper layer was transferred into 2mL Eppendorf tube and 500µL of absolute isopropyl alcohol was added, vortexed, and incubated at room temperature for 10min to precipitate the RNA. The samples were centrifuged (12,000*g*, 10min at 4°C); pellets washed in 1mL of 75% ethanol and air dried (20min). The pellets were suspended in RNasefree DEPC-treated H₂O and stored at −20°C. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to determine the gene expression profiles of sporulation markers. The differential expression of each gene was determined using the Luna® Universal One-Step RT-qPCR Kit. 20μ L reaction mix for each sample includes 10μ L of reaction buffer, 1µL of RT enzyme, 0.8µL each of forward and reverse primers, 5.4µL of nuclease-free water, and 2µL of RNA. The QuantStudio (version 5) was used to analyze the gene expression profiles. Reverse transcription was performed at 55°C for 10min, followed by initial denaturation at 95°C for 1min, denaturation at 95°C for 15 s, extension at 60°C for 15s, and melt curve at 60°C.

Statistical analysis

Descriptive statistics were used in this study (with SPSS 16.0 and GraphPad 6.0), and the data were presented in graphs. Two-way analysis of variance (ANOVA) and correlation analysis were done to compare the level of resistance of the bacterial strains to the tested antibiotics, resistance patterns, and distribution of the sporulation markers relative to the control. $P < 0.05$ was considered as significance level.

Results

Bacillus **species are multidrug resistant**

All the bacterial strains showed resistance to at least four of the ten antibiotics tested relative to the *ATCC 23857* control strain. The highest level of resistance was to cloxacillin, amoxicillin, tetracycline, and ampicillin (Figure 1). The strains showed between 70% and 100% levels of resistance to all the tested antibiotics, with complete resistance (100%) to cloxacillin, amoxicillin, tetracycline, and ampicillin. The antibiotics showed considerable level of effectiveness against the *ATCC 23857* as compared to the tested strains. Overall, the average percentage level of resistance to all the 11 antibiotics tested was 75% with no individual strain susceptible to all the antibiotics. The highest level of resistance was displayed by *B. subtilis*; however, all the strains were multidrug resistant to at least two of the classes of antibiotics tested with different resistance patterns. The minimum inhibitory concentrations vary across the tested antibiotics with $160-480 \,\mathrm{\mu g/mL}$ for cloxacillin, amoxicillin, ampicillin, and tetracycline (Table 1).

Figure 1. Resistance profiles of the bacterial strains to the seven antibiotics tested relative to the *B. subtilis ATCC 23857* control with *P*=0.002 using two-way ANOVA.

VAN: vancomycin; ERY: erythromycin; CHL: chloramphenicol; TMP: trimethoprim; CXC: cloxacillin; GEN: gentamicin; TET: tetracycline; AMP: ampicillin; PEN: penicillin; AMX: amoxicillin.

The rest of other antibiotics tested have an MIC range of 60–120µg/ml with respect to the recommended CLSI standards relative to the ATCC control with 20µg/ml as the least and $60 \mu g/ml$ as the highest (in vancomycin only).

Bacillus **species have multiple sporulation genes**

All the strains, *B. subtilis* and *B. cereus* were screened for the presence of sporulation markers *yrbC*, *sigF*, *sigA*, *spsE*, *spovT*, *spoVK*, *spo0J*, *spoIIIE*, *cotA*, *cotD*, *spsK*, *cotSA*, *spoVE*, *soJ*, *spoII-IAB*, *spo0M*, *spsJ*, *cgeE*, and *spo0A* with PCR-primer specific amplification. *yrbC*, *sigA*, *sigF*, *spoVK*, *cotD*, *spo0J*, *soJ*, *spoII-IAB*, *spo0M*, *spsJ*, *cgeE*, and *spo0A* (Table 2) were detected in all the strains. In addition to these genes, *B. subtilis* have *spoVT*, *spoIIIE*, *cotA*, *spsK*, and *cotSA*. Also, *spoVE* was not detected in all the strains including the control and *spoVT*, *spoIIIE*, and *spsK* only in *B. subtilis*. However, the strains harbors 14 (70%) of the 20 sporulation genes screened with *yrbC*, *sigA*, *sigF*, *cotD*, *spo0J*, *soJ*, *spo0M*, *spsJ*, *cgeE*, and *spo0A* equally distributed in all the strains analyzed (Table 2).

Increase in the expression levels of sporulation markers in response to antibiotic stress

To determine the role of sporulation markers in bacterial resistance profile and associated sporulation, the expression profile of eight sporulation markers, including *SigF*, *SpoVK*, *CotD*, *Spo0J*, *SoJ*, *SpsJ*, *CgeE*, and *Spo0A* was monitored in *B. subtilis* and *B. cereus*. Relative to the control, seven of the sporulation markers were highly expressed in *B. subtilis* (Figure 2) in the presence of cloxacillin, amoxicillin, tetracycline $(160-480 \,\text{µg/mL}$, minimum inhibitory concentrations), and only one in ampicillin at the same concentration. However, the genes were differentially expressed in *B. cereus* (Figure 3). The expressions of all eight genes were increased in response to cloxacillin, while *Spo0J*, *SoJ*, *SpsJ*, and *CgeE* were moderately increased after exposure to amoxicillin, tetracycline, and ampicillin. Most of the markers in *B. cereus* showed a basal level of expression in response to amoxicillin, tetracycline, and ampicillin as compared to *B. subtilis* (Figure 4).

X: variant selected for sporulation markers expression profiling indicating extreme levels of resistance to the tested antibiotics; CXC: cloxacillin; AMX: amoxicillin; AMP: ampicillin; TET: tetracycline; CHL: chloramphenicol; TMP: trimethoprim; VAN: vancomycin; GEN: gentamicin; ERY: erythromycin; PEN: penicillin; CEF: ceftriaxone; +: multiple antibiotic resistant phenotypes (resistance at least to two classes of antibiotics).

Figure 2. Expression profile of sporulation markers in *B. subtilis* (HE1) after exposure to antibiotics. The isolates were exposed to different antibiotics: cloxacillin (HE1- CXC), amoxicillin (HE1-AMX), tetracycline (HE1-TET), and ampicillin (HE1-AMP). The expression profile of eight genes was monitored following exposure to stress: (a) SigF, (b) SpoVK, (c) CotD, (d) Spo0J, (e) SoJ, (f) SpsJ, (g) CgeE, and (h) Spo0A. The samples were analyzed in triplicate using the delta-delta Ct method, and the experimental variations are shown as error bars.

Discussion

Bacillus species are generally known for their ability to form endospores in stringent environmental and clinical conditions.16 These stress factors may include naturally occurring antimicrobial substances (e.g. biocides – disinfectants, surfactants) or clinical antibiotics used to treat *Bacillus*-associated infections.17 Beyond triggering the formation of endospores, these substances could select for bacteria subpopulations that are highly resistant to clinical antibiotics.18 While spores are dispersed into the environments before they germinate and infect, evidences have highlighted their distribution in ICUs of hospitals as potential infectious agents.19,20 This study profiled the expression of sporulation markers in association with multidrug-resistant *B. subtilis* and *B. cereus* isolated from some Ghanaian hospital environments.

The *Bacillus* strains are multidrug resistant to 10 different antibiotics, including vancomycin, amoxicillin, cloxacillin, and penicillin, which are first-line treatment options for *Bacillus-*associated infections. This is similar to the studies conducted elsewhere in Africa and Asia, especially with spore-forming *B. subtilis*,^{5,21,22} confirming that spores contribute to bacterial resistance to antibiotics. A subsequent exposure of the strains to twofold (MIC ×2) and fourfold (MIC \times 4) of the minimum inhibitory concentration showed that a subpopulation of the isolates were resistant at high antibiotic concentrations. Resistance to the selected antibiotic could be as a result of selection pressure or overuse of antibiotics which is a common practice in the ICU. This study suggests that the level of AMR displayed by environmental bacteria from hospitals is increasing, and this can pose a serious threat to public health.

Figure 3. Expression profile of sporulation markers in *B. cereus* (A7) after exposure to antibiotics. The isolates were exposed to different antibiotics: cloxacillin (A7- CXC), amoxicillin (A7-AMX), tetracycline (A7-TET), and ampicillin (A7-AMP). The expression profile of eight genes was monitored following exposure to stress: (a) SigF, (b) SpoVK, (c) CotD, (d) Spo0J, (e) SoJ, (f) SpsJ, (g) CgeE, and (h) Spo0A. The samples were analyzed in triplicate using the delta-delta Ct method, and the experimental variations are shown as error bars.

Figure 4. Comparative differential gene expression profile of sporulation markers between *B. cereus* and *B. subtilis*. Rows represent the sporulation markers and columns represent the fold change in the expression of each gene after exposure to the antibiotics (cloxacillin, amoxicillin, tetracycline, and ampicillin). The color intensity denotes the relative level of expression compared to their respective controls.

Table 2. Detection of sporulation markers

Detection of sporulation markers.

Sporulation markers that have been commonly and uncommonly associated with spore formation in *Bacillus* species were identified. Nineteen of the twenty sporulation markers screened were detected in *B. subtilis* and fourteen in *B. cereus*. Some of these markers, for example, *spoVK*, *spoVE*, *spoJ*, and *sigF* are conserved in *Clostridia* and *Bacillus* species;23,24 while *sigJ*, *soJ*, *yrbC*, and *yjcE* are not commonly reported. In *B. subtilis* and *B. cereus*, *spoVK* and *spoVE* have been associated with morphogenesis^{25,26} encoding ATPbinding motif protein that makes endospores resist heat and antibiotics, 3 which might also account for the high level of resistance observed in this study. *sigF*, an alternative sigma factor, is essential for sporulation¹⁸ and also regulate bacterial persistence and modulates AMR.27 *soJ* and *spo0J* have been associated with Par-system (Par A/B) as possible proteins required for efficient plasmid partitioning from chromosome,²⁸ which is a molecular basis that drives spore formation and germination as well AMR.^{29,30} Although *yrbC* roles in sporulation is poorly understood, however, it has been associated with spore resistance in *B. subtilis*. 31

AMR and sporulation are stress response mechanisms that potentiate survival of environmental pathogens under harsh conditions.32 Sporulation genes have been associated with AMR; however, the intersection of the mechanisms is unclear. In order to ascertain the regulatory roles of sporulation markers in bacterial resistance to antibiotics, expression profiles of eight genes (*SigF*, *SpoVK*, *CotD*, *Spo0J*, *SoJ*, *SpsJ*, *CgeE*, and *Spo0A*) present in all the strains were determined in *B. subtilis* and *B. cereus* (after exposure to cloxacillin, amoxicillin, tetracycline, and ampicillin antibiotics). The strain tested in this study was highly resistant to these antibiotics, even at high concentrations (MIC \times 2/4). The data show increase in expression levels of all the genes in *B. subtilis* in the presence of cloxacillin, amoxicillin, and tetracycline. In *B. cereus*, the expression profile of all the genes increased in response to cloxacillin. Also, *Spo0J*, *SoJ*, *SpsJ*, and *CgeE* were moderately increased after exposure to amoxicillin, tetracycline, and ampicillin. This suggests that sporulation and its associated genetic factors could influence the resistance profiles observed in *Bacillus* spp. against tetracycline, cloxacillin, and other antibiotics. Differences in expression profiles and fold changes could be attributed to variation in resistance patterns to the tested antibiotics and also differences in the concentrations of antibiotics used for the stressed assay. Different bacteria have unique responses and survival mechanisms under stringent conditions, especially with fomite-resident strains as used in this study. Under these conditions, specific markers are triggered with functional relevance.

Overall, this study indicated that spore-forming *Bacillus* species isolated from hospital environments harboring sporulation markers might pose serious public health risks, as they are highly resistant to antibiotics. Also, the findings suggest a possible association between sporulation and AMR that can enhance the survival of *Bacillus* spp. in the environment or within host organisms. There is a need for appropriate antibiotic use and appropriate disinfection practices in the ICU to mitigate spread of spore-forming resistant *Bacillus* species.

Authors' Contributions

AI, EAA, and LM conceptualized and designed the study. AI, EAA, and MKA interpreted and analyzed the data. AI and EAA prepared the first draft of the manuscript. AI and MKA revised the draft for important intellectual content. LM made substantial contributions to the draft, critically reviewed the manuscript. All the authors approved the final draft of the manuscript for submission.

Acknowledgements

The authors appreciate Mosi Research Lab and AMR Research Group led by Dr Abiola Isawumi at the Department of Biochemistry, Cell and Molecular Biology and West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) at the University of Ghana for supports.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: MKA and EAA are supported by a WACCBIP-World Bank ACE PhD fellowship (ACE02-WACCBIP: Awandare) and a DELTAS Africa grant (DEL-15-007: Awandare). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

ORCID iDs

Abiola Isawumi D <https://orcid.org/0000-0003-2141-2509> Lydia Mosi D <https://orcid.org/0000-0002-7672-0181>

References

- 1. Meijer WJ, Castilla-Llorente V, Villar L, Murray H, Errington J, Salas M. Molecular basis for the exploitation of spore formation as survival mechanism by virulent phage phi29. *EMBO J* 2005;**20**:3647–57
- 2. Tan IS, Ramamurthi KS. Spore formation in Bacillus subtilis. *Environ Microbiol Rep* 2014;**3**:212–25
- 3. Setlow P. Spores of Bacillus subtilis: their resistance to and killing by radiation, heat and chemicals. *J Appl Microbiol* 2006;**101**:514–25
- 4. Leggett MJ, McDonnell G, Denyer SP, Setlow P, Maillard JY. Bacterial spore structures and their protective role in biocide resistance. *J Appl Microbiol* 2012;**113**:485–98
- 5. Setlow P. Spore resistance properties. *Microbiol Spectr* 2014;**5**:2
- 6. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. *P T* 2015;**40**:277–83
- 7. Swick MC, Koehler TM, Driks A. Surviving between hosts: sporulation and transmission. *Microbiol Spectr* 2016;**4**:4
- 8. Stephens B, Azimi P, Thoemmes MS, Heidarinejad M, Allen JG, Gilbert JA. Microbial exchange via fomites and implications for human health. *Curr Pollut Rep* 2019;**5**:198–213
- 9. Christelle B, Broussolle V, Carlin F. Sporulation environment influences spore properties in Bacillus: evidence and insights on underlying molecular and physiological mechanisms. *FEMS Microbiol Rev* 2018;**5**:614–26
- 10. Silvaggi JM, Popham DL, Driks A, Eichenberger P, Losick R. Unmasking novel sporulation genes in Bacillus subtilis. *J Bacteriol* 2004;**186**:8089–95
- 11. Paula R, Mónica S, Adriano OH. From root to tips: sporulation evolution and specialization in Bacillus subtilis and the intestinal pathogen *Clostridioides difficile*. *Mol Biol Evol* 2019;**12**:2714–36
- 12. Gu HJ, Sun QL, Luo JC, Zhang J, Sun L. A first study of the virulence potential of a Bacillus subtilis isolate from deep-sea hydrothermal vent. *Front Cell Infect Microbiol* 2019;9
- 13. Schröttner P, Gunzer F, Schüppel J, Rudolph WW. Identification of rare bacterial pathogens by 16S rRNA gene sequencing and MALDI-TOF MS. *J Vis Exp* 2016;**113**:53176
- 14. Abiola I, Abass A, Duodu S, Mosi L. Characterization of culturable airborne bacteria and antibiotic susceptibility profiles of indoor and immediate-outdoor environments of a research institute in Ghana. *AAS Open Res* 2018;**1**:17
- 15. Kirk DG, Dahlsten E, Zhang Z, Korkeala H, Lindström M. Involvement of *Clostridium botulinum* ATCC 3502 sigma factor K in early-stage sporulation. *Appl Environ Microbiol* 2012;**78**:4590–6
- 16. McKenney PT, Driks A, Eichenberger P. The Bacillus subtilis endospore: assembly and functions of the multilayered coat. *Nat Rev Microbiol* 2013;**11**:33–44
- 17. Jones IA, Joshi LT. Biocide use in the antimicrobial era: a review. *Molecules* 2021;**8**:2276
- 18. Kirk DG, Zhang Z, Korkeala H, Lindström M. Alternative sigma factors SigF, SigE, and SigG are essential for sporulation in Clostridium botulinum ATCC 3502. *Appl Environ Microbiol* 2014;**80**:5141–50
- 19. Mallozzi M, Viswanathan VK, Vedantam G. Spore-forming Bacilli and Clostridia in human disease. *Future Microbiol* 2010;**5**:1109–23
- 20. Bryce EA, Smith JA, Tweeddale M, Andruschak BJ, Maxwell MR. Dissemination of Bacillus cereus in an intensive care unit. *Infect Control Hosp Epidemiol* 1993;**8**:459–62
- 21. Balakrishnan S, John KR, George MR. Antibiotic susceptibility of *Bacillus* spp. isolated from shrimp (*Penaeus monodon*) culture pond. *Indian J Mar Sci* 2003;**32**:81–4
- 22. Ikeda M, Yagihara Y, Tatsuno K, Okazaki M, Okugawa S, Moriya K. Clinical characteristics and antimicrobial susceptibility of Bacillus cereus blood stream infections. *Ann Clin Microbiol Antimicrob* 2015; **14**:43
- 23. Galperin MY, Mekhedov SL, Puigbo P, Smirnov S, Wolf YI, Rigden DJ. Genomic determinants of sporulation in Bacilli and Clostridia: towards the minimal set of sporulation-specific genes. *Environ Microbiol* 2012;**14**: 2870–90
- 24. Traag BA, Pugliese A, Eisen JA, Losick R. Gene conservation among endospore-forming bacteria reveals additional sporulation genes in Bacillus subtilis. *J Bacteriol* 2013;**195**:253–60
- 25. McKenney PT, Eichenberger P. Dynamics of spore coat morphogenesis in Bacillus subtilis. *Mol Microbiol* 2012;**83**:245–60
- 26. Henriques AO, De Lencastre H, Piggot PJ. A Bacillus subtilis morphogene cluster that includes spoVE is homologous to the MRA region of *Escherichia coli*. *Biochimie* 1992;**74**:735–48
- 27. Michele TM, Ko C, Bishai WR. Exposure to antibiotics induces expression of the Mycobacterium tuberculosis sigF gene: implications for chemotherapy against mycobacterial persistors. *Antimicrob Agents Chemother* 1999;**43**:218–25
- 28. Leonard TA, Møller-Jensen J, Löwe J. Towards understanding the molecular basis of bacterial DNA segregation. *Philos Trans R Soc Lond B Biol Sci* 2005;**1455**:523–35
- 29. Molle V, Fujita M, Jensen ST, Eichenberger P, Gonzalez-Pastor JE, Liu JS, Losick R. The Spo0A regulon of *Bacillus subtilis. Mol Microbiol* 2003;**50**:1683–701
- 30. Chada VG, Sanstad EA, Wang R, Driks A. Morphogenesis of bacillus spore surfaces. *J Bacteriol* 2003;**185**:6255–61
- 31. Takamatsu H, Kodama T, Nakayama T, Watabe K. Characterization of the yrbA gene of Bacillus subtilis, involved in resistance and germination of spores. *J Bacteriol* 1999;**181**:4986–94
- 32. Sheldon AT Jr. Antibiotic resistance: a survival strategy. *Clin Lab Sci* 2005;**18**:170–80

(Received October 25, 2022, Accepted January 24, 2023)